General Enquiries:
Please note that Paradigm Biopharmaceuticals Ltd is unable to provide medical advice to individuals, and any matters relating to your condition or treatment must be discussed with your GP or specialist.
For general enquiries, please contact us at:
Zilosul is not registered for use in Australia, and we are concentrating our efforts and resources on completing the pivotal clinical trial program in osteoarthritis to seek marketing approval as soon as possible.
At present Paradigm supports the provision of Zilosul in Australia via the TGA Special Access Scheme under limited and specific circumstances.
Access to Zilosul under the SAS can only be requested by medical practitioners, so please ask your doctor to contact us via SASrequests@paradigmbiopharma.com if they wish to receive more information.
Clinical trial enquiries:
Paradigm Biopharmaceuticals Ltd is currently recruiting for clinical trials. All information regarding recruitment activity is published via our ASX announcements and via an appropriate clinical trial registry.
If you would like to register to be kept up to date please complete your details here.
Investor Relations:
Please direct any investor relations enquiries to: